Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.63 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321487 | 1.00 | PIM1 (0.63) | PIM1TYRPIM3PIK3CAMTOR | |
| SCHEMBL1428285 | 0.87 | TYR (0.55) | PIM1TYRPIM3STK17BMEN1 | |
| SCHEMBL4320014 | 0.87 | PIK3CA (0.56) | PIM1TYRPIM3PIK3CAMTOR | |
| SCHEMBL1429461 | 0.87 | PIK3CA (0.56) | PIM1TYRPIM3PIK3CAMTOR | |
| SCHEMBL4315267 | 0.87 | TYR (0.55) | PIM1TYRPIM3STK17BMEN1 | |
| SCHEMBL1428282 | 0.86 | TYR (0.54) | PIM1TYRPIM3PIK3CAMTOR | |
| SCHEMBL4320965 | 0.86 | TYR (0.54) | PIM1TYRPIM3PIK3CAMTOR | |
| SCHEMBL1428302 | 0.82 | ACHE (0.54) | PIM1TYRPIK3CAMTORSTK17B | |
| SCHEMBL4322450 | 0.82 | ACHE (0.54) | PIM1TYRPIK3CAMTORSTK17B | |
| SCHEMBL3227995 | 0.82 | PIK3CA (0.58) | PIM1PIK3CAMTORSTK17BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | claimed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | claimed |
| EP-2300460-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009155042-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311217-A1 | 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, PDPK1 | PIM1 137/4885TYR 490/4885PIM3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.